Image Ben Hargreaves R&D Mpox is on the rise again as outbreak gathers pace The original mpox outbreak began in 2022, but case numbers have rumbled on, despite countermeasures. Market Access Drug pricing overhaul sparks tension with industry Up until recently, political rhetoric targeting the pharma industry had been largely all bark and no bite. R&D Drug repositioning to bring forgotten assets from shelves to... A problem very rarely spoken about is the treatments that are promising, but are not developed further. Patients Power to the patients: Patient organisations enabling drug d... Drug development is a complex process and there are many stakeholders involved in bringing treatments to patients. Load more results
R&D Mpox is on the rise again as outbreak gathers pace The original mpox outbreak began in 2022, but case numbers have rumbled on, despite countermeasures.
Market Access Drug pricing overhaul sparks tension with industry Up until recently, political rhetoric targeting the pharma industry had been largely all bark and no bite.
R&D Drug repositioning to bring forgotten assets from shelves to... A problem very rarely spoken about is the treatments that are promising, but are not developed further.
Patients Power to the patients: Patient organisations enabling drug d... Drug development is a complex process and there are many stakeholders involved in bringing treatments to patients.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
